What Caused Arrowhead Pharmaceuticals to Skyrocket 10.5% Today
After the company announced it has filed for approval with New Zealand regulators to begin phase 1 studies of its hepatitis B RNAi therapy, shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) shot 10.5% higher at 3:30 p.m. EST Friday.
Arrowhead Pharmaceuticals was forced to abandon all of its clinical-stage therapies in 2016 following regulators' concerns over liver toxicity. The news devastated shares and forced the company back to the drawing board to develop a new RNA delivery system.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Arrowhead Pharmaceuticals Inc. Stock
€27.10
4.000%
The stock is one of the favorites of our community with 32 Buy predictions and 2 Sell predictions.
With a target price of 42 € there is a hugely positive potential of 54.98% for Arrowhead Pharmaceuticals Inc. compared to the current price of 27.1 €.
